IL15抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07376(IL15 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07376(IL15 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Interleukin-15 (IL-15) is a pleiotropic cytokine critical for immune system regulation, particularly in the survival, proliferation, and activation of natural killer (NK) cells, CD8+ memory T cells, and innate lymphoid cells. It shares structural and functional similarities with IL-2 but has distinct roles in maintaining immune homeostasis and promoting anti-tumor immunity. Dysregulated IL-15 signaling is implicated in autoimmune diseases (e.g., rheumatoid arthritis, celiac disease) and cancer progression, making it a therapeutic target.

IL-15 antibodies are designed to modulate this pathway. Neutralizing antibodies can block IL-15 binding to its receptor (IL-15Rα/γc), suppressing pro-inflammatory responses in autoimmune conditions. Conversely, agonist antibodies or IL-15/IL-15Rα complexes are explored in immunotherapy to enhance NK and T cell activity against tumors. Challenges include optimizing antibody specificity, pharmacokinetics, and minimizing off-target effects. For example, monoclonal antibodies like AMG 714 (anti-IL-15) have shown promise in celiac disease trials, while engineered IL-15 superagonists (e.g., N-803) are being tested in cancer. Research continues to address toxicity concerns and improve delivery mechanisms, highlighting IL-15's dual role as a therapeutic target or enhancer depending on disease context.